Ayotunde Omoz-Oarhe, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acquired Immunodeficiency Syndrome | 2 | 2023 | 2203 | 0.590 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2024 | 2187 | 0.480 |
Why?
|
Isoniazid | 5 | 2024 | 281 | 0.450 |
Why?
|
HIV Infections | 11 | 2025 | 17533 | 0.440 |
Why?
|
Tuberculosis | 5 | 2024 | 2012 | 0.380 |
Why?
|
Rifampin | 5 | 2022 | 351 | 0.300 |
Why?
|
Latent Tuberculosis | 2 | 2022 | 223 | 0.290 |
Why?
|
Hepatitis B Vaccines | 1 | 2025 | 178 | 0.220 |
Why?
|
Antitubercular Agents | 5 | 2024 | 1384 | 0.200 |
Why?
|
Abortion, Spontaneous | 2 | 2024 | 536 | 0.200 |
Why?
|
Tuberculosis, Pulmonary | 2 | 2022 | 838 | 0.190 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 219 | 0.170 |
Why?
|
Adjuvants, Immunologic | 1 | 2025 | 995 | 0.160 |
Why?
|
Hepatitis B | 1 | 2025 | 707 | 0.160 |
Why?
|
Contraceptive Agents, Female | 1 | 2020 | 123 | 0.160 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2022 | 392 | 0.150 |
Why?
|
Anti-HIV Agents | 3 | 2024 | 4559 | 0.150 |
Why?
|
Benzoxazines | 3 | 2024 | 320 | 0.140 |
Why?
|
Anti-Retroviral Agents | 2 | 2023 | 1787 | 0.140 |
Why?
|
Pregnancy Outcome | 2 | 2024 | 2966 | 0.130 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2019 | 664 | 0.120 |
Why?
|
Premature Birth | 2 | 2024 | 1829 | 0.120 |
Why?
|
Alkynes | 2 | 2024 | 326 | 0.100 |
Why?
|
Cyclopropanes | 2 | 2024 | 437 | 0.100 |
Why?
|
HIV | 3 | 2024 | 1585 | 0.090 |
Why?
|
Nevirapine | 2 | 2022 | 273 | 0.090 |
Why?
|
Papillomavirus Infections | 1 | 2022 | 1640 | 0.090 |
Why?
|
Medroxyprogesterone Acetate | 2 | 2022 | 153 | 0.090 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2022 | 2047 | 0.090 |
Why?
|
Pregnancy | 4 | 2024 | 30260 | 0.080 |
Why?
|
Incidence | 1 | 2023 | 21480 | 0.060 |
Why?
|
Alum Compounds | 1 | 2025 | 35 | 0.060 |
Why?
|
Aluminum Hydroxide | 1 | 2025 | 55 | 0.060 |
Why?
|
Hepatitis B Antibodies | 1 | 2025 | 156 | 0.060 |
Why?
|
Guanine | 1 | 2025 | 282 | 0.050 |
Why?
|
Immunization Schedule | 1 | 2025 | 228 | 0.050 |
Why?
|
Adult | 9 | 2025 | 223044 | 0.050 |
Why?
|
Mass Screening | 2 | 2022 | 5446 | 0.050 |
Why?
|
Young Adult | 3 | 2024 | 59889 | 0.050 |
Why?
|
Oxazines | 1 | 2024 | 358 | 0.050 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 295 | 0.050 |
Why?
|
Stillbirth | 1 | 2024 | 381 | 0.050 |
Why?
|
Adolescent | 3 | 2023 | 88835 | 0.040 |
Why?
|
Female | 10 | 2025 | 396112 | 0.040 |
Why?
|
CD4 Lymphocyte Count | 2 | 2019 | 2587 | 0.040 |
Why?
|
Vaginal Smears | 1 | 2022 | 513 | 0.040 |
Why?
|
Pregnancy Trimester, First | 1 | 2024 | 919 | 0.040 |
Why?
|
Pyridones | 1 | 2024 | 816 | 0.040 |
Why?
|
Africa | 1 | 2020 | 725 | 0.040 |
Why?
|
Pharmacogenetics | 1 | 2022 | 682 | 0.040 |
Why?
|
Drug Interactions | 1 | 2022 | 1417 | 0.030 |
Why?
|
Humans | 12 | 2025 | 765968 | 0.030 |
Why?
|
Reference Standards | 1 | 2020 | 1013 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2020 | 967 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2022 | 1141 | 0.030 |
Why?
|
Middle Aged | 3 | 2025 | 223009 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2024 | 26346 | 0.030 |
Why?
|
Piperazines | 1 | 2024 | 2549 | 0.030 |
Why?
|
Sweating | 1 | 2013 | 155 | 0.020 |
Why?
|
Bacteriological Techniques | 1 | 2013 | 276 | 0.020 |
Why?
|
Prevalence | 2 | 2022 | 15842 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4850 | 0.020 |
Why?
|
Sputum | 1 | 2013 | 513 | 0.020 |
Why?
|
Africa South of the Sahara | 1 | 2013 | 751 | 0.020 |
Why?
|
Peru | 1 | 2013 | 887 | 0.020 |
Why?
|
Cough | 1 | 2013 | 597 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2019 | 6309 | 0.020 |
Why?
|
Brazil | 1 | 2013 | 1248 | 0.020 |
Why?
|
Standard of Care | 1 | 2013 | 567 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 3236 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2013 | 1441 | 0.020 |
Why?
|
Medication Adherence | 1 | 2019 | 2192 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 26318 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2013 | 1315 | 0.020 |
Why?
|
India | 1 | 2013 | 2334 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2013 | 2627 | 0.020 |
Why?
|
Fever | 1 | 2013 | 1603 | 0.020 |
Why?
|
Mycobacterium tuberculosis | 1 | 2013 | 1917 | 0.010 |
Why?
|
Infant | 1 | 2024 | 36386 | 0.010 |
Why?
|
Male | 4 | 2025 | 363698 | 0.010 |
Why?
|
Weight Loss | 1 | 2013 | 2710 | 0.010 |
Why?
|
Child, Preschool | 1 | 2022 | 42500 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15398 | 0.010 |
Why?
|
Child | 1 | 2022 | 80564 | 0.010 |
Why?
|
Algorithms | 1 | 2013 | 14071 | 0.010 |
Why?
|
Prospective Studies | 1 | 2013 | 54802 | 0.000 |
Why?
|
Aged | 1 | 2021 | 171117 | 0.000 |
Why?
|